Core Viewpoint - Zhendemedical experienced a decline of 2.37% on February 2, with a trading volume of 87.14 million yuan, indicating a potential market reaction to recent financial performance and trading activity [1]. Financing Summary - On February 2, Zhendemedical had a financing buy-in amount of 14.04 million yuan, with a net financing buy of 7.70 million yuan, reflecting strong investor interest despite the stock price drop [1]. - The total financing and securities balance reached 1.41 billion yuan, accounting for 7.89% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of leverage [1]. - The company had no shares repaid in the securities lending market on February 2, with 100 shares sold, resulting in a selling amount of 6,714 yuan, and a securities lending balance of 1.03 million yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.18 billion yuan, representing a year-on-year growth of 1.88%, while the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period, with an average of 11,308 circulating shares per shareholder, a decrease of 3.90% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with an increase of 190,000 shares, while the fund "Zhaoshang Core Competitiveness Mixed A" exited the top ten list [3].

Core Viewpoint - The company, Steady Medical, has reported rapid growth in its high-end dressing segment within its medical business, indicating a strong potential for future expansion in both domestic and international markets [1] Group 1: Business Performance - The high-end dressing category is identified as a strategic product line with significant growth [1] - The gross profit margin for this segment is relatively high, contributing positively to the company's financial health [1] Group 2: Market Dynamics - The overseas market for high-end dressings has reached a mature stage, suggesting established demand and competitive positioning [1] - The domestic market is still in the promotion phase, indicating substantial room for growth and market penetration in the future [1]

【导读】下周2只新股可申购，恒运昌是半导体设备核心零部件供应商 中国基金报记者 闻言 A股打新投资者注意啦！ 根据目前发行安排，下周有2只新股可申购，分别是北交所新股爱舍伦、上交所科创板新股恒运昌，具 体申购时间分别是1月12日、1月16日。 爱舍伦是医用敷料领域头部企业 爱舍伦的申购代码是920050，发行价为15.98元/股，发行市盈率为14.99倍，参考行业市盈率为29.79 倍。 爱舍伦此次总发行数量为1692万股，网上发行数量为1523万股。投资者参与网上申购爱舍伦，申购数量 上限为76.13万股。 爱舍伦作为一家医用敷料生产商，主要从事应用在专业康复护理与医疗防护领域的一次性医用耗材研 发、生产和销售，通过ODM（原始设计制造商）/OEM（原始设备制造商）等方式为国际知名医疗器械 品牌厂商提供相关产品。 近年来，爱舍伦的重要客户包含Medline集团、Zarys International Group、Sejong Healthcare Co., Ltd.、苏 州鼎康进出口有限公司、San Pablo Commercial Corp.等。 2022年至2024年及2025年上半年，爱舍伦的营业收入 ...

Core Insights - Aishalon Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District [2] - The company's stock opened with a significant increase of 224.78%, reaching a total market capitalization of 3.49 billion yuan [2] Company Overview - Aishalon Medical focuses on the research, production, and sales of disposable medical consumables in the fields of rehabilitation care and surgical infection control [3] - The company has established long-term strategic partnerships with several international medical device brands, including Medline Group from the U.S., Zarys Group from Poland, and Sejong Healthcare from South Korea [3] - Aishalon is recognized as the largest manufacturer of medical care pads in China, with annual output value exceeding 500 million yuan from 2022 to 2024, positioning itself among the top players in the domestic medical dressing industry [3] Financial Performance - From 2022 to 2024, Aishalon's operating revenue grew from 574 million yuan to 692 million yuan, while net profit increased from 63 million yuan to 81 million yuan, demonstrating a steady compound annual growth rate [4] - For the first nine months of 2025, the company achieved an operating revenue of 689 million yuan, a year-on-year increase of 42.84%, and a net profit of 73 million yuan, up 27.50% from the previous year [4] - The company has maintained a high proportion of overseas sales revenue, which reached 96.54% in the first half of 2025, indicating its strong role in the global supply chain [4] Industry Context - The medical dressing industry is characterized by rigid demand, driven by global aging populations, increasing surgical volumes, and heightened infection control awareness [5] - The market for medical dressings is expected to continue growing steadily, with a trend towards high-quality, multifunctional, and disposable products [5] Growth Strategy - Aishalon plans to use the funds raised from its IPO to invest in the "Kaipule Public Health Medical Supplies Industrial Park" project, aimed at expanding production capacity and developing new product lines [6] - The company is transitioning from a single dressing production focus to a broader medical consumables manufacturing and service platform, which is expected to reduce dependency on single products and clients [6] - Aishalon is also expanding its global production footprint, with existing bases in Thailand and plans for new facilities in Morocco, showcasing its strategic vision to adapt to international trade dynamics and cost pressures [6]

Company and Industry Summary Company: Aisheren (920050) Key Points - **Core Business Focus**: Aisheren specializes in medical dressings, particularly in rehabilitation care and surgical infection control products. The company emphasizes a "core customer" strategy, collaborating closely with major clients to iteratively develop products based on demand and optimize manufacturing processes [1][2]. - **Major Client**: Medline Group has been the largest customer from 2022 to 2024, accounting for over 70% of Aisheren's revenue. This strong client relationship is pivotal for the company's revenue stability and growth [3]. - **Market Trends**: Two primary growth drivers are identified: 1. Enhanced safety and hygiene standards in operating rooms, aligning with practices in Europe and the US. 2. Increased demand for elderly care, opening up opportunities in the consumer market [3]. - **Medline's Global Position**: Medline is recognized as the largest manufacturer and distributor of surgical supplies globally and the fourth largest medical device company. It went public on NASDAQ in December 2025, raising approximately $2.26 billion, which will be invested in local markets and global expansion, as well as supply chain upgrades [3]. - **Capacity Expansion**: Aisheren faced capacity constraints before 2024, but with the commissioning of a factory in Thailand, revenue growth is expected to accelerate. For 2024, revenue and profit growth rates are projected to increase significantly, with year-on-year growth of 20.4% and 20.5% respectively, and for Q3 2025, growth rates are expected to be 42.8% and 27.5% respectively [3]. - **Future Production Plans**: The company plans to continue expanding production capacity in 2026 and 2027, with expected increases of 50% and 30% respectively. New facilities in various locations, including domestic and international sites, will produce customized products, including precision urine bags [3]. - **Investment Outlook**: The low-value consumables market is a necessity for medical institutions, and the global market is steadily expanding. International leading brands are increasing their international business, and contract manufacturers are likely to benefit from shared market expansion opportunities [3].

Group 1: Lin Qingxuan (02657HK) Overview - Lin Qingxuan is a leading high-end domestic skincare brand in China, established in 2003, focusing on the "oil-based skincare" concept using camellia oil as a core ingredient [2][11][13] - The company's revenue is projected to grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, with a CAGR of 32.7%, while net profit is expected to turn from a loss of 6 million yuan to a profit of 187 million yuan, representing a 120% year-on-year increase in 2024 [2][11][13] - The brand's market share in the high-end skincare segment is 1.4%, making it the only domestic representative among the top 15 high-end skincare brands in China for 2024 [11][13] Group 2: Market Trends and Opportunities - The skincare market in China has reached a scale of 400 billion yuan, with significant growth potential in per capita spending compared to Western markets [11][13] - The segment of facial essence oils is expected to grow at a CAGR of 42.8% from 2019 to 2024, significantly outpacing the overall industry growth [11][13] - The high-end skincare market is projected to expand to 218.5 billion yuan by 2029, driven by the mainstream adoption of the "oil-based skincare" concept [11][13] Group 3: Product and Channel Strategy - Lin Qingxuan has successfully upgraded its core product, the camellia essence oil, to its fifth generation, achieving cumulative sales of over 45 million bottles and maintaining the top position in the national facial essence oil sales for 11 consecutive years [11][13] - The company is enhancing its product matrix with stable growth in other products like creams and essence waters, while also focusing on R&D breakthroughs to improve product efficacy [11][13] - The brand's omnichannel strategy includes nearly 600 physical stores and a strong online presence, with online sales accounting for 65.4% of total revenue in the first half of 2025 [11][13] Group 4: Financial Projections - The projected net profits for Lin Qingxuan from 2025 to 2027 are 347 million yuan, 577 million yuan, and 820 million yuan, respectively, with year-on-year growth rates of 86%, 66%, and 42% [11][13] - The price-to-earnings (PE) ratios for the same years are expected to be 31, 18, and 13 times, indicating a favorable valuation outlook [11][13] Group 5: Hong Kong Stock Market Analysis - The "January Effect" in the Hong Kong stock market is attributed to the return of overseas investors and the gradual inflow of foreign capital into Chinese assets, which is expected to continue [4][12][14] - The market's liquidity environment has improved compared to the end of the previous year, with a notable increase in trading activity and a decrease in short-selling [14] - Despite the positive trends, the market remains sensitive to fluctuations in overseas risk appetite and domestic economic conditions [14]

Core Viewpoint - The article emphasizes the importance of disposable medical consumables in modern healthcare, highlighting the leading position of Jiangsu Aisheren Medical Technology Group Co., Ltd. in this sector, driven by innovation and quality manufacturing [1][2]. Group 1: Company Overview - Jiangsu Aisheren was established in 2015, with roots tracing back to 2003, focusing on rehabilitation care and medical infection control [2]. - The company has developed a diverse product matrix, including medical care pads, ice bags, surgical gowns, and surgical kits, serving various healthcare settings [2]. - Aisheren has become one of the top ten exporters of medical dressings in China, with multiple production bases both domestically and internationally [3]. Group 2: Innovation and Competitive Advantage - Aisheren has built a strong competitive edge through process and product innovations, achieving full automation in production processes, which reduces reliance on manual labor and enhances efficiency [2][3]. - The company has upgraded its core products using composite technology, significantly improving physical strength and comfort, with specific products achieving high load capacities and moisture permeability [3]. Group 3: Market Position and Client Relationships - Aisheren has established a robust quality management system and has received multiple international certifications, making it a core supplier for major global brands like Medline and Zarys International Group [4][5]. - The company operates on an ODM/OEM business model, actively participating in product design and development, which strengthens client relationships and enhances product offerings [5]. Group 4: Financial Performance - Aisheren's revenue has shown rapid growth, with 2024 revenue projected at 6.92 billion yuan, a 20.56% increase from the previous year, and a significant rise in net profit [6][8]. - The company’s main business gross margin has remained stable between 22% and 23%, indicating strong cost control and product competitiveness [11]. Group 5: Market Demand and Future Prospects - The global medical dressing market is expected to grow from $9 billion in 2011 to $23.5 billion by 2026, driven by aging populations and increased healthcare standards [13][20]. - Aisheren plans to raise 300 million yuan for expanding production capacity and optimizing its product structure, aiming to enhance its product matrix with high-value items [21][22].

Group 1: A-share New Stock Offerings - This week (January 12 - January 16), there are two new stocks available for subscription in the A-share market: Aisheren on the Beijing Stock Exchange and Hengyun Chang on the Sci-Tech Innovation Board, with subscriptions starting on Monday and Friday respectively [1] Group 2: Aisheren Overview - Aisheren's issue price is 15.98 yuan per share, with a single account subscription limit of 761,300 shares [2] - The company focuses on medical health, primarily engaged in the R&D, production, and sales of disposable medical consumables for rehabilitation care and medical protection, providing products like medical care pads and surgical kits [2] - Aisheren has established four production bases in operation, three under construction, and two planned, positioning itself as a leading player in the domestic medical dressing industry [2] Group 3: Aisheren Financial Performance - For the fiscal years 2022 to 2024, Aisheren's projected revenues are 574 million yuan, 575 million yuan, and 692 million yuan, with net profits of 63 million yuan, 67 million yuan, and 81 million yuan respectively [3] Group 4: Aisheren Fundraising Purpose - The funds raised will be invested in the construction of the Kaipule Public Health Medical Supplies Industrial Park [4] Group 5: Hengyun Chang Overview - Hengyun Chang has a single account subscription limit of 4,000 shares, requiring a minimum market value of 40,000 yuan in the Shanghai market for maximum subscription [5] - The company is a leading supplier of core components for semiconductor equipment, focusing on the R&D, production, and sales of plasma RF power systems and related components [5] Group 6: Hengyun Chang Product Development - Hengyun Chang has developed three generations of products over ten years, with its semiconductor-grade plasma RF power systems starting mass delivery in the second half of 2020, breaking the foreign monopoly in this field [6] - The Bestda series supports 28nm processes, while the latest Aspen series supports advanced processes of 7-14nm, achieving performance metrics comparable to American competitors [6] Group 7: Hengyun Chang Financial Performance - For the fiscal years 2022 to 2024, Hengyun Chang's projected revenues are 158 million yuan, 325 million yuan, and 541 million yuan, with net profits of 26 million yuan, 80 million yuan, and 142 million yuan respectively [6] Group 8: Hengyun Chang Fundraising Purpose - The funds raised will be allocated to the industrialization of semiconductor RF power systems, the establishment of an intelligent production operation base for core components, a research and innovation center, a marketing and technical support center, and to supplement working capital [6]

Group 1: A-share New IPOs - Two new stocks available for subscription next week: Aisheren on January 12 and Hengyunchang on January 16 [1] - Aisheren is a leading company in the medical dressing sector, focusing on disposable medical consumables for rehabilitation and medical protection [2][3] Group 2: Aisheren Financials - Aisheren's subscription code is 920050, with an issue price of 15.98 yuan per share and a P/E ratio of 14.99, compared to the industry average of 29.79 [3] - Total shares issued by Aisheren are 16.92 million, with 15.23 million available for online subscription, and a maximum subscription limit of 761,300 shares [3] - Aisheren's projected revenues for 2025 are between 890 million and 940 million yuan, representing a year-on-year growth of 28.65% to 35.89% [5] - Historical revenue figures for Aisheren from 2022 to 2025 are 574 million, 575 million, 692 million, and 438 million yuan respectively, with net profits of 62.8 million, 66.96 million, 80.71 million, and 49.68 million yuan [3][4] Group 3: Hengyunchang Overview - Hengyunchang's subscription code is 787785, with the issue price and P/E ratio yet to be disclosed, but the industry average P/E is 39.32 [7] - The company specializes in core components for semiconductor equipment, including plasma RF power systems and related technology services [7][9] - Hengyunchang has been recognized as a national-level "specialized and innovative" enterprise, filling a gap in domestic high-end semiconductor equipment applications [9] Group 4: Hengyunchang Financials - Hengyunchang's historical revenue from 2022 to 2025 is 158 million, 325 million, 541 million, and 304 million yuan respectively, with net profits of 26.19 million, 79.83 million, 142 million, and 69.35 million yuan [9][10] - Projected revenues for Hengyunchang in 2025 are estimated between 489 million and 515 million yuan, indicating a decline of 9.58% to 4.69% year-on-year [13][14] - The company's net profit forecast for 2025 is between 102 million and 114 million yuan, reflecting a decrease of 28.21% to 19.54% compared to the previous year [13][14]

Group 1: A-share New IPOs - Two new stocks available for subscription next week: Aisheren on January 12 and Hengyunchang on January 16 [2] - Aisheren is a leading company in the medical dressing field, focusing on the R&D, production, and sales of disposable medical consumables [3][5] - Aisheren's subscription code is 920050, with an issue price of 15.98 yuan per share and a P/E ratio of 14.99, compared to the industry average of 29.79 [4] Group 2: Aisheren Financials - Aisheren plans to issue 16.92 million shares, with 15.23 million available for online subscription, and a maximum subscription limit of 761,300 shares [5] - Revenue projections for Aisheren from 2022 to 2025 are 574 million yuan, 575 million yuan, 692 million yuan, and 438 million yuan for the first half of 2025, respectively [5] - Expected revenue for 2025 is between 890 million yuan and 940 million yuan, representing a year-on-year growth of 28.65% to 35.89% [7][8] Group 3: Hengyunchang Overview - Hengyunchang is a core component supplier for semiconductor equipment, specializing in plasma RF power systems and related technologies [9][10] - The subscription code for Hengyunchang is 787785, with the issue price and P/E ratio yet to be disclosed, but the industry average P/E is 39.32 [9] - Hengyunchang plans to issue 16.93 million shares, with 4.06 million available for online subscription, and a maximum subscription limit of 4,000 shares [9] Group 4: Hengyunchang Financials - Revenue for Hengyunchang from 2022 to 2025 is projected at 158 million yuan, 325 million yuan, 541 million yuan, and 304 million yuan for the first half of 2025, respectively [10] - Expected revenue for 2025 is between 489 million yuan and 515 million yuan, indicating a year-on-year decline of 9.58% to 4.69% [13][16] - Projected net profit for 2025 is between 102 million yuan and 114 million yuan, reflecting a decrease of 28.21% to 19.54% compared to the previous year [13][16]